| [1] |
Park JW, Chen M, Colombo M, et al. Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE study[J]. Liver Int, 2015, 35(9):2155-2166.
|
| [2] |
中国抗癌协会肝癌专业委员会转化治疗协作组. 肝癌转化治疗中国专家共识(2021版)[J]. 中华消化外科杂志, 2021, 20(6):600-616.
|
| [3] |
El-Khoueiry AB, Sangro B, Yau T, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial[J]. Lancet, 2017, 389(10088):2492-2502.
|
| [4] |
Finn RS, Qin S, Ikeda M, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma[J]. N Engl J Med, 2020, 382(20):1894-1905.
|
| [5] |
Marsee A, Roos FJM, Verstegen MMA, et al. Building consensus on definition and nomenclature of hepatic, pancreatic, and biliary organoids[J]. Cell Stem Cell, 2021, 28(5):816-832.
|
| [6] |
Rebouissou S, Nault JC. Advances in molecular classification and precision oncology in hepatocellular carcinoma[J]. J Hepatol, 2020, 72(2):215-229.
|
| [7] |
Boyault S, Rickman DS, de Reyniès A, et al. Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets[J]. Hepatology, 2007, 45(1):42-52.
|
| [8] |
Hoshida Y, Nijman SMB, Kobayashi M, et al. Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma[J]. Cancer Res, 2009, 69(18):7385-7392.
|
| [9] |
Schulze K, Imbeaud S, Letouzé E, et al. Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets[J]. Nat Genet, 2015, 47(5):505-511.
|
| [10] |
Nicholes K, Guillet S, Tomlinson E, et al. A mouse model of hepatocellular carcinoma: ectopic expression of fibroblast growth factor 19 in skeletal muscle of transgenic mice[J]. Am J Pathol, 2002, 160(6):2295-2307.
|
| [11] |
Kim RD, Sarker D, Meyer T, et al. First-in-human phaseⅠstudy of fisogatinib (BLU-554) validates aberrant FGF19 signaling as a driver event in hepatocellular carcinoma[J]. Cancer Discov, 2019, 9(12): 1696-1707.
|
| [12] |
Arao T, Ueshima K, Matsumoto K, et al. FGF3/FGF4 amplification and multiple lung metastases in responders to sorafenib in hepatocellular carcinoma[J]. Hepatology, 2013, 57(4):1407-1415.
|
| [13] |
Zhang Y, Wang X. Targeting the Wnt/β-catenin signaling pathway in cancer[J]. J Hematol Oncol, 2020, 13(1):165.
|
| [14] |
álvarez-Fernández M, Malumbres M. Mechanisms of sensitivity and resistance to CDK4/6 inhibition[J]. Cancer Cell, 2020, 37(4):514-529.
|
| [15] |
Seligmann JF, Fisher DJ, Brown LC, et al. Inhibition of WEE1 is effective in TP53- and RAS-mutant metastatic colorectal cancer:a randomized trial (FOCUS4-C) comparing adavosertib (AZD1775) with active monitoring[J]. J Clin Oncol, 2021, 39(33):3705-3715.
|
| [16] |
Shi HS, Wang S, Li MJ, et al. A hepatocellular carcinoma patient with TSC1 mutations benefits from treatment with everolimus: a case report[J]. Visc Med, 2021, 37(2):116-119.
|
| [17] |
Lu X, Paliogiannis P, Calvisi DF, et al. Role of the mammalian target of rapamycin pathway in liver cancer: from molecular genetics to targeted therapies[J]. Hepatology, 2021, 73 Suppl 1(Suppl 1):49-61.
|
| [18] |
Pilié PG, Gay CM, Byers LA, et al. PARP inhibitors: extending benefit beyond BRCA-mutant cancers[J]. Clin Cancer Res, 2019, 25(13):3759-3771.
|
| [19] |
Chen Q, Xie C, Feng K, et al. Response to crizotinib in a patient with MET-amplified hepatocellular carcinoma[J]. Hepatol Res, 2021, 51(11):1164-1169.
|
| [20] |
Benson AB, D'Angelica MI, Abbott DE, et al. Hepatobiliary cancers, version 2.2021, NCCN clinical practice guidelines in oncology[J]. J Natl Compr Canc Netw, 2021, 19(5):541-565.
|
| [21] |
Qiu Z, Li H, Zhang Z, et al. A pharmacogenomic landscape in human liver cancers[J]. Cancer Cell, 2019, 36(2):179-193, e11.
|
| [22] |
Gillet JP, Calcagno AM, Varma S, et al. Redefining the relevance of established cancer cell lines to the study of mechanisms of clinical anti-cancer drug resistance[J]. Proc Natl Acad Sci U S A, 2011, 108(46):18708-18713.
|
| [23] |
Loong JH, Wong TL, Tong M, et al. Glucose deprivation-induced aberrant FUT1-mediated fucosylation drives cancer stemness in hepatocellular carcinoma[J]. J Clin Invest, 2021, 131(11):e143377.
|
| [24] |
Wozniak MA, Modzelewska K, Kwong L, et al. Focal adhesion regulation of cell behavior[J]. Biochim Biophys Acta, 2004, 1692(2/3):103-119.
|
| [25] |
Aref AR, Huang RY, Yu W, Yu W, et al. Screening therapeutic EMT blocking agents in a three-dimensional microenvironment[J]. Integr Biol, 2013, 5(2):381-389.
|
| [26] |
Hirt C, Papadimitropoulos A, Mele V, et al. "In vitro" 3D models of tumor-immune system interaction[J]. Adv Drug Deliv Rev, 2014(79/80):145-154.
|
| [27] |
Hu B, Li H, Guo W, et al. Establishment of a hepatocellular carcinoma patient-derived xenograft platform and its application in biomarker identification[J]. Int J Cancer, 2020, 146(6):1606-1617.
|
| [28] |
Xu W, Zhao ZY, An QM, et al. Comprehensive comparison of patient-derived xenograft models in hepatocellular carcinoma and metastatic liver cancer[J]. Int J Med Sci, 2020, 17(18):3073-3081.
|
| [29] |
Morgan KM, Riedlinger GM, Rosenfeld J, et al. Patient-derived xenograft models of non-small cell lung cancer and their potential utility in personalized medicine[J]. Front Oncol, 2017(7):2.
|
| [30] |
Dunn GP, Old LJ, Schreiber RD. The three Es of cancer immunoediting[J]. Annu Rev Immunol, 2004(22):329-360.
|
| [31] |
Prieto J, Melero I, Sangro B. Immunological landscape and immunotherapy of hepatocellular carcinoma[J]. Nat Rev Gastroenterol Hepatol, 2015, 12(12):681-700.
|
| [32] |
Lee JS, Ruppin E. Multiomics prediction of response rates to therapies to inhibit programmed cell death 1 and programmed cell death 1 ligand 1[J]. JAMA Oncol, 2019, 5(11):1614-1618.
|
| [33] |
Gatalica Z, Xiu J, Swensen J, et al. Comprehensive analysis of cancers of unknown primary for the biomarkers of response to immune checkpoint blockade therapy[J]. Eur J Cancer, 2018(94): 179-186.
|
| [34] |
Yu JH, Ma S. Organoids as research models for hepatocellular carcinoma[J]. Exp Cell Res, 2022, 411(1):112987.
|
| [35] |
Aizarani N, Saviano A, Sagar, et al. A human liver cell atlas reveals heterogeneity and epithelial progenitors[J]. Nature, 2019, 572(7768): 199-204.
|
| [36] |
Broutier L, Mastrogiovanni G, Verstegen MM, et al. Human primary liver cancer–derived organoid cultures for disease modeling and drug screening[J]. Nat Med, 2017, 23(12):1424-1435.
|
| [37] |
Kondo J, Ekawa T, Endo H, et al. High-throughput screening in colorectal cancer tissue-originated spheroids[J]. Cancer Sci, 2019, 110(1):345-355.
|
| [38] |
Nuciforo S, Fofana I, Matter MS, et al. Organoid models of human liver cancers derived from tumor needle biopsies[J]. Cell Rep, 2018, 24(5):1363-1376.
|
| [39] |
Liu J, Li P, Wang L, et al. Cancer-associated fibroblasts provide a stromal niche for liver cancer organoids that confers trophic effects and therapy resistance[J]. Cell Mol Gastroenterol Hepatol, 2021, 11(2):407-431.
|
| [40] |
Neal JT, Li X, Zhu J, et al. Organoid modeling of the tumor immune microenvironment[J]. Cell, 2018, 175(7):1972-1988, e16.
|
| [41] |
Scherberich A, Galli R, Jaquiery C, et al. Three-dimensional perfusion culture of human adipose tissue-derived endothelial and osteoblastic progenitors generates osteogenic constructs with intrinsic vascularization capacity[J]. Stem Cells, 2007, 25(7):1823-1829.
|
| [42] |
Vlachogiannis G, Hedayat S, Vatsiou A, et al. Patient-derived organoids model treatment response of metastatic gastrointestinal cancers[J]. Science, 2018, 359(6378):920-926.
|
| [43] |
Yao Y, Xu X, Yang L, et al. Patient-derived organoids predict chemoradiation responses of locally advanced rectal cancer[J]. Cell Stem Cell, 2020, 26(1):17-26, e6.
|
| [44] |
Hou S, Tiriac H, Sridharan BP, et al. Advanced development of primary pancreatic organoid tumor models for high-throughput phenotypic drug screening[J]. SLAS Discov, 2018, 23(6):574-584.
|
| [45] |
Li L, Knutsdottir H, Hui K, et al. Human primary liver cancer organoids reveal intratumor and interpatient drug response heterogeneity[J]. JCI Insight, 2019, 4(2):e121490.
|